ArticleBiomaterials and biosystems2026
Electrochemical sensor based on MWCNTs/ZnONPs for detection of prostate specific antigen.
Article in Biomaterials and biosystems, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An electrochemical immunosensor based on multiwalled carbon nanotube/zinc oxide nanoparticle (MWCNTs/ZnONPs) composites was fabricated for the sensitive and selective detection of prostate-specific antigen (PSA), an established biomarker for early prostate cancer diagnosis. The MWCNTs/ZnONPs-modified screen-printed carbon electrode (SPCE) provided an enlarged electroactive surface area and enhanced electron transfer kinetics, thereby improving the overall analytical performance. Monoclonal anti-PSA antibodies were covalently immobilized on the composite surface and PSA quantification was conducted using cyclic voltammetry (CV) and differential pulse voltammetry (DPV). Under optimized experimental conditions, the biosensor exhibited a linear response toward PSA concentrations ranging from 5 to 200 ng mL⁻¹, with a detection limit of 5 ng mL⁻¹ (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.